Drug intelligence / Profile preview

LS-05

Development stage: Preclinical
Lead developer: LentiStem Biotech
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

LS-05 is a preclinical-stage chimeric antigen receptor (CAR) T-cell therapy being developed by LentiStem Biotech, a Spanish biotechnology company specializing in lentiviral vector-based therapies. The candidate is designed to treat solid tumors and leverages the company's proprietary Lent-On-Plus platform, which aims to enhance the safety and efficacy of CAR-T cells by providing controlled transgene expression. As of 2024, the specific biological target of LS-05 has not been publicly disclosed, and the program is in the early proof-of-concept or preclinical stage of development.

Other names: LS_05

Beyond the preview

Go deeper on LS-05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LS-05.

Explore the full profile